Table 3

Serum miRNAs in ovarian cancer
Cohort Subtype Stage RNA origin Platform Result Reference
2 cancer unknown IV 1 mL serum microarray (custom) Clustered with other cancers and separate from normals [32]
9 cancer Mixed, 60% serous I-IV 250uL serum TaqMan qRT-PCR array 21 differentially expressed miRNA including miR-21, 92, 93, 29a, 126 [27]
4 normal ----
19 cancer Mixed, 60% serous I-IV 250uL serum TaqMan qRT-PCR Assays (normalizer: miR-142-3p) Increased in cancer versus normal: miR-21, 92, 93, 29a, 126 [27]
11 normal ----
4 cancer serous IV Matched tumor and serum (exosomes from 2.5 mL serum) microarray (custom) Similar levels between tumor and serum suggesting a tumor origin for: miR-21, 141, 200a, 200b, 200c, 203, 205 [15]
30 cancer serous I (10) Exosomes from 2.5 mL serum microarray (custom) Increased in cancer versus benign: miR-21, 141, 200a, 200b, 200c, 203, 205, 214, 215 [15]
II (10)
III (10)
10 benign adenoma ----
28 cancer Serous II-IV 500 uL serum TaqMan qRT-PCR Assays (normalizer: miR-103) Increased in cancer versus normal: miR-200a, 200b, 200c This study
28 normal Age-matched ----

Kan et al.

Kan et al. BMC Cancer 2012 12:627   doi:10.1186/1471-2407-12-627

Open Data